Similar articles

• The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge.

  Andriole G, Bostwick D, Civantos F, Epstein J, Lucia MS, McConnell J, Roehrborn CG. Andriole G, et al. J Urol. 2005 Dec;174(6):2098-104. doi: 10.1097/01.ju.0000181216.71605.38. J Urol. 2005. PMID: 16280736 Review.
• New drugs for the prostate.

  [No authors listed] [No authors listed] Harv Mens Health Watch. 2005 Jun;9(11):3-8. Harv Mens Health Watch. 2005. PMID: 16138402 No abstract available.
• The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations.

  Marks LS, Andriole GL, Fitzpatrick JM, Schulman CC, Roehrborn CG. Marks LS, et al. J Urol. 2006 Sep;176(3):868-74. doi: 10.1016/j.juro.2006.04.024. J Urol. 2006. PMID: 16890642 Review.
• The use of 5α-reductase inhibitors for the prevention and treatment of prostate cancer.

  Cha EK, Shariat SF. Cha EK, et al. Eur Urol. 2011 Apr;59(4):515-7. doi: 10.1016/j.eururo.2011.01.028. Epub 2011 Jan 25. Eur Urol. 2011. PMID: 21277077 No abstract available.
• New 5alpha-reductase inhibitors: in vitro and in vivo effects.

  Pérez-Ornelas V, Cabeza M, Bratoeff E, Heuze I, Sánchez M, Ramírez E, Naranjo-Rodríguez E. Pérez-Ornelas V, et al. Steroids. 2005 Mar;70(3):217-24. doi: 10.1016/j.steroids.2004.11.008. Steroids. 2005. PMID: 15763601